Pamrevlumab Plus Nab-Paclitaxel/gemcitabine (pam + GA) As First- and Second-Line Therapy in Metastatic Pancreatic Cancer (mpdac): Results from Precision Promise (prp) Bayesian Platform Trial.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined